Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10874128 | 0.89 | POLB (0.49) | POLBHCAR2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL2570620 | 0.84 | KMT2A (0.55) | POLBHCAR2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL12677900 | 0.82 | HPGD (0.57) | HCAR2SMN1; SMN2MAPTHPGDKMT2A | |
| SCHEMBL1516680 | 0.81 | HTT (0.66) | POLBHCAR2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL10875034 | 0.81 | POLB (0.47) | POLBHCAR2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL30964507 | 0.80 | POLB (0.58) | POLBHCAR2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL5429432 | 0.80 | HPGD (0.49) | SMN1; SMN2MAPTRAB9ANPC1TSHR | |
| SCHEMBL9525018 | 0.79 | POLB (0.45) | POLBHCAR2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL16758459 | 0.78 | POLB (0.60) | POLBHCAR2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL27690353 | 0.77 | HPGD (0.47) | HCAR2SMN1; SMN2MAPTL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208973-A1 | TETRACYCLIC COMPOUNDS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-06-27 | — | — | US | disclosed |
| CN-117337289-A | Tetracyclic compounds for the treatment of brain disorders | 加利福尼亚大学董事会 | 2024-01-02 | — | — | CN | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023115060-A1 | PSYCHOPLASTOGENS FOR TREATING HEARING-RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2021076572-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-8071611-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-22 | — | — | US | disclosed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | disclosed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1551404-A2 | METHOD OF INHIBITING ANGIOGENESIS | Abbott Laboratories (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004032908-A2 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | GRIN1, GRIN2A, GRIN3B | POLB 4509/4885HCAR2 999/4885KDM4E 2082/4885 |
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | POLB 1128/4885HCAR2 1694/4885KDM4E 3402/4885 |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | POLB 1128/4885HCAR2 1694/4885KDM4E 3402/4885 |
| US-20040067985-A1 | Method of inhibiting angiogenesis | VEGFA, PGF, FLT4 | POLB 1457/4885HCAR2 2104/4885KDM4E 3429/4885 |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | POLB 3203/4885HCAR2 585/4885KDM4E 1300/4885 |
| US-20240208973-A1 | TETRACYCLIC COMPOUNDS FOR TREATING BRAIN DISORDERS | GRIN2A, GRIN2C, DCX | POLB 4408/4885HCAR2 581/4885KDM4E 3151/4885 |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | POLB 4369/4885HCAR2 36/4885KDM4E 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.